Skip to main content

Esketamine News

Postpartum Low-Dose Esketamine Aids Moms With Prenatal Depression

MONDAY, April 15, 2024 – A single low dose of esketamine after childbirth reduces depressive episodes at 42 days postpartum among mothers with prenatal depression, according to a study published...

Ketamine Nasal Spray Shows Promise Against Tough-to-Treat Depression

THURSDAY, Oct. 5, 2023 – A nasal spray containing a ketamine derivative appears to beat one of the standard drugs used for people with difficult-to-treat depression, a new clinical trial has found....

Esketamine Nasal Spray Beneficial for Treatment-Resistant Depression

THURSDAY, Oct. 5, 2023 – For patients with treatment-resistant depression, esketamine nasal spray is superior to extended-release quetiapine with respect to remission at week 8, according to a study...

FDA Approves Spravato (esketamine) CIII Nasal Spray to Treat Depressive Symptoms in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior

TITUSVILLE, N.J. – (August 3, 2020) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug ...

FDA Approves Spravato (esketamine) Nasal Spray for Treatment-Resistant Depression

March 5, 2019 – The U.S. Food and Drug Administration today approved Spravato (esketamine) nasal spray, in conjunction with an oral antidepressant, for the treatment of depression in adults who have...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

Major Depressive Disorder, Depression

Esketamine patient information at Drugs.com